Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.
Ocular Therapeutix said Tuesday that its experimental treatment, called Axpaxli, maintained vision with less frequent injections compared to a standard treatment for patients with a common cause of age-related blindness — achieving the primary goal o... [684 chars]